Jim Simons’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.04M | Buy |
454,374
+75,000
| +20% | +$391K | ﹤0.01% | 1881 |
|
|
2025
Q4 | $2.33M | Buy |
379,374
+357,700
| +1,650% | +$2.59M | ﹤0.01% | 1766 |
|
|
2025
Q3 | $157K | Sell |
21,674
-426,700
| -95% | -$2.53M | ﹤0.01% | 3184 |
|
|
2025
Q2 | $2.38M | Buy |
448,374
+198,600
| +80% | +$1.17M | ﹤0.01% | 2010 |
|
|
2025
Q1 | $2.22M | Sell |
249,774
-435,100
| -64% | -$5.23M | ﹤0.01% | 1936 |
|
|
2024
Q4 | $9.39M | Buy |
684,874
+319,500
| +87% | +$5.9M | 0.01% | 1053 |
|
|
2024
Q3 | $10M | Buy |
+365,374
| New | +$9.89M | 0.02% | 1036 |
|
|
2023
Q1 | – | Sell |
-14,974
| Closed | -$217K | – | 4255 |
|
|
2022
Q4 | $217K | Sell |
14,974
-154,800
| -91% | -$2.88M | ﹤0.01% | 3381 |
|
|
2022
Q3 | $3.24M | Buy |
169,774
+76,574
| +82% | +$1.76M | ﹤0.01% | 1713 |
|
|
2022
Q2 | $1.69M | Sell |
93,200
-2,274
| -2% | -$47.2K | ﹤0.01% | 2314 |
|
|
2022
Q1 | $2.41M | Buy |
95,474
+57,500
| +151% | +$1.47M | ﹤0.01% | 2092 |
|
|
2021
Q4 | $1.05M | Sell |
37,974
-173,600
| -82% | -$5.03M | ﹤0.01% | 2607 |
|
|
2021
Q3 | $6.83M | Buy |
211,574
+139,900
| +195% | +$4.65M | 0.01% | 1270 |
|
|
2021
Q2 | $2.19M | Buy |
+71,674
| New | +$2.07M | ﹤0.01% | 2195 |
|
|
2021
Q1 | – | Sell |
-49,491
| Closed | -$979K | – | 3575 |
|
|
2020
Q4 | $979K | Sell |
49,491
-58,483
| -54% | -$944K | ﹤0.01% | 2513 |
|
|
2020
Q3 | $1.41M | Buy |
107,974
+55,974
| +108% | +$708K | ﹤0.01% | 2318 |
|
|
2020
Q2 | $590K | Buy |
+52,000
| New | +$738K | ﹤0.01% | 2810 |
|
|
2020
Q1 | – | Sell |
-95,900
| Closed | -$2.61M | – | 3666 |
|
|
2019
Q4 | $2.61M | Buy |
+95,900
| New | +$2.64M | ﹤0.01% | 2192 |
|
|
2018
Q3 | – | Sell |
-36,800
| Closed | -$1.38M | – | 3486 |
|
|
2018
Q2 | $1.38M | Sell |
36,800
-178,474
| -83% | -$6.03M | ﹤0.01% | 2459 |
|
|
2018
Q1 | $6.36M | Sell |
215,274
-2,005
| -0.9% | -$67.8K | 0.01% | 1661 |
|
|
2017
Q4 | $7.46M | Buy |
217,279
+57,105
| +36% | +$1.93M | 0.01% | 1563 |
|
|
2017
Q3 | $5.79M | Buy |
+160,174
| New | +$4.57M | 0.01% | 1677 |
|
|
2017
Q2 | – | Sell |
-534,700
| Closed | -$10.3M | – | 3309 |
|
|
2017
Q1 | $10.3M | Sell |
534,700
-2,151,474
| -80% | -$38.1M | 0.01% | 1229 |
|
|
2016
Q4 | $44.8M | Sell |
2,686,174
-245,500
| -8% | -$4.44M | 0.07% | 377 |
|
|
2016
Q3 | $60.3M | Buy |
2,931,674
+1,599,374
| +120% | +$40.6M | 0.11% | 213 |
|
|
2016
Q2 | $40.8M | Buy |
1,332,300
+297,500
| +29% | +$10.3M | 0.08% | 328 |
|
|
2016
Q1 | $38.7M | Buy |
1,034,800
+85,200
| +9% | +$3.21M | 0.07% | 327 |
|
|
2015
Q4 | $41M | Buy |
949,600
+93,000
| +11% | +$3.93M | 0.09% | 262 |
|
|
2015
Q3 | $32.1M | Buy |
856,600
+216,800
| +34% | +$7.69M | 0.08% | 309 |
|
|
2015
Q2 | $21.7M | Buy |
639,800
+366,100
| +134% | +$12.4M | 0.05% | 496 |
|
|
2015
Q1 | $9.69M | Buy |
273,700
+179,700
| +191% | +$6.43M | 0.02% | 956 |
|
|
2014
Q4 | $3.2M | Buy |
94,000
+33,526
| +55% | +$1.19M | 0.01% | 1537 |
|
|
2014
Q3 | $2.33M | Buy |
60,474
+11,274
| +23% | +$421K | 0.01% | 1592 |
|
|
2014
Q2 | $1.92M | Sell |
49,200
-13,600
| -22% | -$506K | ﹤0.01% | 1753 |
|
|
2014
Q1 | $2.15M | Sell |
62,800
-299,900
| -83% | -$9.29M | 0.01% | 1732 |
|
|
2013
Q4 | $7.61M | Sell |
362,700
-2,171,331
| -86% | -$54.9M | 0.02% | 947 |
|
|
2013
Q3 | $59.5M | Buy |
2,534,031
+254,657
| +11% | +$7.23M | 0.14% | 136 |
|
|
2013
Q2 | $61.2M | Buy |
+2,279,374
| New | +$66.1M | 0.16% | 128 |
|
Other funds holding MYGN
O
GCM
VCM
VPM
Jim Simons's MYGN Position: Q1 2026 in Review
Jim Simons increased its Myriad Genetics (MYGN) stake by 20% in Q1 2026, buying an estimated $391K and bringing the position to 454,374 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1881.
Jim Simons first reported a position in MYGN in Q2 2013 and has held it in 38 quarters since. The position peaked at $61.2M in Q2 2013. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.
- Jim Simons held 454,374 shares of Myriad Genetics worth $2.04M as of Q1 2026.
- Jim Simons bought 75,000 Myriad Genetics shares in Q1 2026, an estimated $391K.
- Myriad Genetics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1881 holding.
- Jim Simons first reported a position in Myriad Genetics in Q2 2013 and has held it in 38 quarters since.
- Jim Simons's Myriad Genetics position peaked at $61.2M in Q2 2013.
- 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.